Table 4.
Comparison of patients’ outcomes receiving endoscopic ablation according to tumor grade.
| Low Grade | High Grade | p Value | |
|---|---|---|---|
| N | 6 | 17 | |
| Age, mean ± SD (yr) | 63.2 ± 18.0 | 69.0 ± 10.4 | 0.343 |
| Gender (M/F) | 2/4 | 9/8 | 0.640 |
| Tumor location (RP c/w Ureter/Ureter alone) | 1/5 | 8/9 | 0.340 |
| cT1 vs. cTa | 0/6 | 8/9 | 0.058 |
| Previous/Conc. UC (Yes/No) | 4/2 | 9/8 | 0.660 |
| Tumor Size (≥3/<3 cm) | 1/5 | 3/13 | 0.999 |
| Adjuvant IVCT (Yes/No) | 1/5 | 1/16 | 0.463 |
| CIS (Yes/No) | 0/6 | 0/17 | 1.00 |
| Bladder tumor recurrence (Yes/No) | 0/6 | 8/9 | 0.058 |
| Any urinary tract recurrence | 1/5 | 13/4 | 0.018 |
| Subsequent RNU (Yes/No) | 1/5 | 8/9 | 0.340 |
| Progression (Yes/No) | 1/5 | 3/14 | 0.999 |
| Death (Yes/No) | 1/5 | 3/14 | 0.999 |
SD, standard deviation; M, male; F, female; RP, renal pelvis; Conc., concomitant; UC, urothelial carcinoma; c/w, with/without; IVCT, intravesical chemotherapy; CIS, carcinoma in situ; RNU, radical nephroureterectomy.